Surgical oncologist Sam Yoon spoke about a rare genetic mutation that increases the likelihood of developing gastric cancer and the prophylactic surgery some patients are opting to receive to reduce their chances of developing the disease.
Victor Ribaudo, Executive Director of Memorial Sloan Kettering’s Regional Care Network, commented on the construction progress of Memorial Sloan Kettering’s newest regional center set to open in Harrison, New York, in 2015.
Memorial Sloan Kettering Board member David M. Rubenstein spoke about his $10 million contribution to establish a new pancreatic cancer research center at the hospital, and Department of Surgery Vice Chair Ronald DeMatteo commented on the need for progress against the deadly disease.
Medical oncologist Clifford Hudis commented on a new study that found that extending tamoxifen therapy for an additional five years in some women with breast cancer reduced the risk of disease recurrence and death.
Surgical oncologist Monica Morrow discussed a study she co-authored that found that more than three-quarters of women who opt for double mastectomies are not getting any benefit because their risk of cancer developing in the healthy breast is no greater than in women without cancer.
Diagnostic radiologist Carol Lee discussed a study that analyzed 30 years of data on breast cancer incidence and suggested that as many as a third of cancers detected through routine mammograms may not be life threatening. Epidemiologist Colin Begg also commented on the study in Reuters and Nature, and Memorial Sloan Kettering’s Breast Disease Management Team authored a letter to the editor about the study that was published in the New York Times.
Just three weeks after medical oncologist Leonard Saltz, epidemiologist Peter Bach, and Physician-in-Chief Robert Wittes authored an opinion piece on Memorial Sloan Kettering’s decision not to carry a new colorectal cancer drug due to its cost, the pharmaceutical company said it would cut the price of the drug in half.